tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Wei, 3 are a SELL (9.09%), 3 are a HOLD (9.09%), 27 are a BUY (81.82%).
Analyst Thomas Wei, currently employed carries an average stock price target met ratio of 83.33% that have a potential upside of 68.3% achieved within 587 days. Previously, Thomas Wei worked at JEFFERIES.
Thomas Wei’s has documented 68 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on STML, Stemline Therapeutics at 22-Apr-2015.
Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 5/6/2013. The price target of $18 was fulfilled within 35 days with a profit of $5.82 (47.78%) receiving and performance score of 13.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
1 years 1 days ago
(20-Nov-2023)
1/3 (33.33%)
$-0.04 (-0.99%)
300
Hold
$1
$-0.07 (-6.54%)
$5
1 years 27 days ago
(25-Oct-2023)
4/21 (19.05%)
$0.29 (40.85%)
32
Sell
$1
$-0.07 (-6.54%)
$3.5
1 years 4 months 2 days ago
(19-Jul-2023)
8/11 (72.73%)
$-0.08 (-7.41%)
55
Hold
$1.25
$0.18 (16.82%)
$2
1 years 4 months 2 days ago
(19-Jul-2023)
2/5 (40%)
$0.17 (15.74%)
215
Buy
$10
2 years 4 months 30 days ago
(22-Jun-2022)
13/47 (27.66%)
$6.81 (213.48%)
194
What Year was the first public recommendation made by Thomas Wei?
